Odevixibat Scratches the Itch of Kids' Rare Liver Disease Phase III trial showed reduced pruritus in progressive familial intrahepatic cholestasis Jul 08, 2022
Which Biologics Stick Longest for Psoriasis? British data highlight factors affecting drug longevity Jul 06, 2022
Does Sunlight Trigger Lupus? Analysis of data from major study suggests "yes," but falls short of clear conclusion Jun 22, 2022
Health Equity, Gun Violence Prevention Among Priorities for AMA's New President Jack Resneck, Jr., MD, talks about running "the race we're in" Jun 15, 2022
FDA Approves First Systemic Treatment for Alopecia Areata Four to 10 times as many patients met hair-regrowth endpoint with JAK inhibitor versus placebo Jun 13, 2022
Something Fishy About Tuna and Melanoma Risk Higher total fish intake linked with 22% higher risk of malignant tumors Jun 09, 2022
Novel IL-17 Inhibitor Passes Mid-Stage Test in Psoriatic Arthritis Phase II results suggest drug could outperform existing agents Jun 03, 2022
Why the Atypical Symptoms in the Latest Monkeypox Cases? Experts agree these cases are unusual, but not necessarily a concern for viral mutation May 27, 2022
Lance Bass' Psoriatic Arthritis "I just figured it was because of dancing," says former member of 'NSYNC May 26, 2022
FDA OKs First Novel Nonsteroidal Topical for Plaque Psoriasis in 25 Years Complete, near-complete clearance in 35-40% of patients treated with tapinarof cream 1% May 24, 2022
Oral Retinoid May Ease Painful Skin Reactions to Anticancer Therapy Preliminary data on acitretin therapy are promising May 11, 2022
In Lupus, 'Normal-Appearing' Skin Is Not Normal Groundwork for inflammation laid before lesions develop Apr 27, 2022
Testing for Th/To Antibodies May Help in Scleroderma Management Test identifies patients at high risk for pulmonary hypertension Apr 25, 2022
FDA OKs New Topical for Inflammatory Rosacea Almost half of patients clear of lesions or nearly so with benzoyl peroxide 5% cream (Epsolay) Apr 25, 2022
Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1 But response rate driven primarily by injected lesions, expert points out Apr 14, 2022
Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1 Six-month PFS rate more than doubled with nivolumab/ipilimumab versus ipilimumab alone Apr 13, 2022
Response in Kids With Psoriasis Maintained Long Term With IL-17A Inhibitor At least 75% improvement at 108 weeks in patients treated with ixekizumab Apr 13, 2022
Smoker's Painless Skin Nodules Flag a Fatal Diagnosis Skin metastasis was the first sign for the otherwise asymptomatic patient Apr 04, 2022
First Topical Therapy for Facial Angiofibroma Nabs FDA Approval New alternative to dermabrasion, laser treatment, surgery Apr 04, 2022
Chronic Spontaneous Urticaria Responds Quickly to BTK Inhibitor AAD data also promising for therapies in psoriasis, pyoderma gangrenosum Mar 31, 2022
Psoriasis Therapy Has Mixed Effects on Cardiovascular Risk Factors No reduction in vascular inflammation with apremilast but significant reduction in body fat Mar 30, 2022
Meta-Analysis of Atopic Dermatitis Drugs Favors Two JAK Inhibitors Small advantages for abrocitinib, upadacitinib, but data still accumulating for all the players Mar 30, 2022
Toward More Uniform Methotrexate Dosing in Psoriasis International expert group urges common standards Mar 30, 2022
Jada Pinkett Smith's Alopecia The condition at the center of this year's Academy Awards drama Mar 29, 2022
Significant Improvement in Vitiligo With JAK Inhibitor Therapy Durable improvement in pigmentation with topical ruxolitinib, oral ritlecitinib Mar 29, 2022
Atopic Dermatitis: Promising Data for New Mechanistic Approach Rapid responses in a majority of patients in small trial of eblasakimab Mar 28, 2022
Targeted Antibody Provides Significant Relief From Itchy Nodular Condition Dupilumab reduces itch, lesion count in first phase III trial for prurigo nodularis Mar 28, 2022
Dramatic, Durable Hair Growth With Oral JAK Inhibitor Oral baricitinib superior to placebo at 36 weeks in BRAVE-AA1 and BRAVE-AA2 trials Mar 27, 2022
Novel Fixed-Dose Immunotherapy Combo Wins FDA Approval Nivolumab plus relatlimab doubled progression-free survival in unresectable melanoma Mar 21, 2022
Mixed Message for Ultrasound in High-Risk Cutaneous Head and Neck Cancer Nodal metastasis detected more often than by clinical exam, worrisome false-positive rate Mar 18, 2022
Clinic-Based Hidradenitis Suppurativa Surgery Gets High Marks From Patients High satisfaction after three-fourths of procedures, despite frequent recurrences Mar 17, 2022
Extension Study Confirms JAK Inhibitor's Activity in Atopic Dermatitis EASI75 response rate exceeding 80% through 52 weeks of upadacitinib treatment Mar 16, 2022
FDA Warns on Using Surgical Device for Aesthetic Skin Procedures Agency details potentially life-threatening adverse events with plasma-generating device Mar 14, 2022
Novel Therapies Active in Head and Neck Cancers High response rate with oncolytic virus plus immunotherapy in cutaneous lesions Feb 28, 2022
Merkel Cell Carcinoma Much More Likely to Recur vs Other Skin Cancers 5-year recurrence rate was 40% compared with 19% for melanoma Feb 23, 2022
Predicting Treatment Response in Inflammatory Muscle Disorders Swedish registry study elicits factors associated with improvement Feb 16, 2022
Acute Muscle Weakness and Skin Rash Following a Lupus Diagnosis Clinicians consider many differentials Feb 14, 2022
Two Years On, Tremfya Still Shines in Psoriatic Arthritis Efficacy increases in long-term extension data Feb 10, 2022
Hair Loss Drugs Ranked in Order of Efficacy Meta-analysis attempts a head-to-head comparison Feb 07, 2022
Evidence Begins to Gel for Atopic Dermatitis, Multiple Comorbid Conditions Atopic, metabolic, cardiovascular, and mental health conditions cited in guideline update Feb 02, 2022
